LimFlow
- Industry
- Medical Devices
- Founded Year
- 2012
- Headquarters
- Paris, France
- Employee Count
- 0
Key People
- Dan Rose - CEO
- Martin Rothman, MD - Co-founder
- Tim Lenihan - Co-founder
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: LimFlow's leadership includes experienced MedTech entrepreneurs.
The presence of multiple successful MedTech entrepreneurs in LimFlow's leadership team suggests a strong foundation for innovation and execution in the medical device sector.
- Clinical Need
-
Aspect: Very Strong
Summary: LimFlow addresses a critical unmet need in treating CLTI.
Chronic limb-threatening ischemia (CLTI) represents a severe stage of peripheral artery disease with limited treatment options, making LimFlow's solution highly valuable.
- Competition
-
Aspect: First mover
Summary: LimFlow is the first FDA-approved device for TADV.
Being the first FDA-approved device for transcatheter arterialization of deep veins (TADV) positions LimFlow advantageously in the market.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology is innovative yet manageable.
While developing a novel medical device involves challenges, LimFlow's technology appears to be within predictable technical parameters.
- Patent
-
Aspect: Strong
Summary: LimFlow holds strong patents for its technology.
Strong patent protection enhances LimFlow's competitive position and potential for market exclusivity.
- Financing
-
Aspect: Strategics
Summary: LimFlow has secured strategic funding, including from Inari Medical.
Strategic investments, particularly from industry players like Inari Medical, provide not only capital but also valuable industry insights and potential synergies.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: LimFlow has achieved FDA approval and reimbursement milestones.
Obtaining FDA approval and securing reimbursement are critical steps for commercial success in the medical device industry.
Opportunity Rollup
- Odds of Success
- 3.4
- Peak Market Share
- 4.3
- Segment CAGR
- 4.4%
- Market Segment
- Peripheral Vascular Devices
- Market Sub Segment
- Chronic Limb-Threatening Ischemia Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.21 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
LimFlow's innovative approach to treating CLTI positions it strongly in a growing market, supported by experienced leadership and strategic investments.